FDA March 3, 2021

By: Janet Woodcock, M.D., Acting Commissioner of Food and Drugs, and Amy Abernethy, M.D., Ph.D., Principal Deputy Commissioner & Acting Chief Information Officer

With the near ubiquity of interconnected smartphones and computers in modern life, it can be difficult to remember just how quickly our familiarity with data has evolved. Data, in digital form, seem to be everywhere we look. Yet, we are still at an early stage in our ability to apply data to understand and treat disease and address other public health challenges. At this early stage, even small advances in our ability to gain useful insights from data can represent significant opportunities.

In September 2019, when we announced the U.S. Food and Drug Administration’s Technology Modernization Action Plan (TMAP)...

Today's Sponsors

Teladoc Health

Today's Sponsors

Canton & Company

Today's Sponsor


Topics: Big Data, FDA, Govt Agencies, Healthcare System, Public Health, Technology
The FDA Seeks a New Way to Review Old Drugs Without Causing Prices to Soar
To Improve Competition In Generic Drug Markets, The FDA Should Discount User Fees For Small Players
FDA-cleared AI devices lack critical information on performance, equity
FDA greenlights Medtronic's AI tool that finds polyps during colonoscopies
Digital Twins 101